Inhibitory effects of 190 compounds against SARS‐CoV‐2 Mpro protein: Molecular docking interactions

Author:

Souza Gabriella B.1,Sens Larissa1ORCID,Hammerschmidt Stefan J.2ORCID,de Sousa Natália F.3ORCID,de Carvalho Maryelle A. G.1,Dos Santos Carlos V. D.1,Tizziani Tiago1ORCID,Moreira Monalisa A.1,Pollo Luiz A. E.4ORCID,Martin Erlon F.4,Neto José S. S.1ORCID,Biavatti Maique W.4ORCID,de Assis Francisco F.1ORCID,Ngadjui Bonaventure T.5ORCID,Simo Ingrid K.6ORCID,Ambassa Pantaléon5,Scotti Marcus T.3ORCID,Scotti Luciana3ORCID,Braga Antonio L.1ORCID,Schirmeister Tanja2ORCID,Sandjo Louis P.1ORCID

Affiliation:

1. Department of Chemistry, CFM Universidade Federal de Santa Catarina, Campus Universitário‐Trindade Florianópolis Santa Catarina Brazil

2. Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg‐University of Mainz Mainz Germany

3. Chemistry Department, Exact and Nature Sciences Center Federal University of Paraiba, Campus I João Pessoa Paraíba Brazil

4. Department of Pharmaceutical Sciences, CCS Universidade Federal de Santa Catarina Florianópolis Santa Catarina Brazil

5. Department of Organic Chemistry Faculty of Science University of Yaoundé 1 Yaoundé Cameroon

6. Department of Chemistry University of Dschang Dschang Cameroon

Abstract

AbstractCOVID‐19 has caused many deaths since the first outbreak in 2019. The burden on healthcare systems around the world has been reduced by the success of vaccines. However, population adherence and the occurrence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants are still challenging tasks to be affronted. In addition, the newly approved drug presents some limitations in terms of side effects and drug interference, highlighting the importance of searching for new antiviral agents against SARS‐CoV‐2. The SARS‐CoV‐2 main protease (Mpro) represents a versatile target to search for new drug candidates due to its essential role in proteolytic activities responsible for the virus replication. In this work, a series of 190 compounds, composed of 27 natural ones and 163 synthetic compounds, were screened in vitro for their inhibitory effects against SARS‐CoV‐2 Mpro. Twenty‐five compounds inhibited Mpro with inhibitory constant values (Ki) between 23.2 and 241 µM. Among them, a thiosemicarbazone derivative was the most active compound. Molecular docking studies using Protein Data Bank ID 5RG1, 5RG2, and 5RG3 crystal structures of Mpro revealed important interactions identified as hydrophobic, hydrogen bonding and steric interactions with amino acid residues in the active site cavity. Overall, our findings indicate the described thiosemicarbazones as good candidates to be further explored to develop antiviral leads against SARS‐CoV‐2. Moreover, the studies showed the importance of careful evaluation of test results to detect and exclude false‐positive findings.

Funder

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3